Table 3 Concise literature on research undertaken with NC-based drug formulations

Bexarotene

Oral

Breast and prostate cancer

631; 0.33; + 24.6

[81]

5-flurouracil

I.V

Colorectal cancer

69.53 ± 1.14

[82]

Resveratrol

I.P

Ehrlich’s ascites tumor

270; 0.31

[83]

Paclitaxel

I.V., I.P., I.T., Oral

All benign tumors

118–397; < 0.3;

− 20.87 ~  + 52.5

[84,85,86,87,88,89,90]

Docetaxel

I.V., intravaginal

Breast-, head and neck-, stomach-, hormone-resistant prostate cancer

70–526; 0.3 < ;

− 20.8 ~  + 10.4

[91,92,93]

Cabazitaxel

I.V

Breast cancer

110

[47]

Campothecin

I.V

Breast cancer

80–700; 0.128;

− 11.4 ~ − 28.5

[94, 95]

Salinomycin

Oral

Colorectal cancer

210 ± 10

[96]

Amoitone B

I.V

Anti-cancer

256.3; 0.206;

− 21.52

[97]

Anlotinib

I.V

Hepatocellular carcinoma

200;/; − 30

[98]

Nintedanib

Oral

Non-small cell lung cancer

325; 0.22; + 32.70

[99]

Curcumin

I.V

Inhibits cell proliferation and migration

158–749; 0.156;

− 29.1

[100]

Flubendazole

I.P

Lung cancer

253; 0.358;

− 30.45

[101]

Carfilzomib

I.V

Breast cancer

270–328; 0.27;

− 13.7

[102]

Parthenolide

I.V

Advanced hepatocellular carcinoma

126–208; 0.230;

− 11.18

[103]